Osman Oguz Demir

Osman Oguz Demir

Auto-generated profile, based on publicly available information

Osman Oguz Demir

Department of Pediatric Infectious Diseases Hacettepe University Faculty of Medicine Ankara Türkiye

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2023 in Pediatrics International
Verified
Journal Article
Closed access
YOYasemin Ozsurekci
Yasemin Ozsurekci
Kubra AykacKubra Aykac
Kubra Aykac
ODOsman Oguz Demir
Osman Oguz Demir
SISare Ilbay
Sare Ilbay
SKSelman Kesici
Selman Kesici
ACAli Bulent Cengiz
Ali Bulent Cengiz

14 February 2025 in The Pediatric Infectious Disease Journal
Verified
Journal Article
Closed access
ODOsman Oguz Demir
Osman Oguz Demir
KAKubra Aykac
Kubra Aykac
EAEce Aslan
Ece Aslan
HKHande Kahya
Hande Kahya
SASema Aydin
Sema Aydin
YOYasemin Ozsurekci
Yasemin Ozsurekci

30 January 2026 in Infectious Diseases and Clinical Microbiology
Verified
Journal Article
Open access
Kubra AykacKubra Aykac
Kubra Aykac
ODOsman Oğuz Demir
Osman Oğuz Demir
BMBahar Madran
Bahar Madran
YOYasemin Ozsurekci
Yasemin Ozsurekci
Onder ErgonulOnder Ergonul
Onder Ergonul
Objective: Childhood vaccination is a cornerstone of public health, significantly reducing morbidity and mortality from vaccine-preventable infectious diseases. However, vaccine hesitancy and refusal have emerged as growing global concerns that may undermine immunization efforts. This study aimed to synthesize the existing literature to provide a comprehensive overview of the prevalence, trends, and key determinants of childhood vaccine hesitancy and refusal in Türkiye. Materials and Methods: This systematic review and meta-analysis was conducted in accordance with PRISMA guidelines and registered in PROSPERO (CRD 42024513557). A comprehensive literature search was performed in PubMed, Web of Science, Scopus, MEDLINE, and the Cochrane Library for studies published up to March 1, 2024. Risk of bias was assessed using the Joanna Briggs Institute (JBI) Critical Appraisal Tool for Prevalence Studies. Results: A total of nine studies involving 15,429 participants were included. The pooled prevalence of vaccine hesitancy was 15% (95% CI, 11%–20%), while the pooled prevalence of vaccine refusal was 3% (95% CI, 2%–6%). Substantial heterogeneity was observed among studies for both outcomes (vaccine hesitancy: I²=96.9%, τ²=0.2053, p<0.0001; vaccine refusal: I²=97.8%, τ²=0.8517, p<0.0001). Vaccine hesitancy was more pronounced in certain regions, particularly Central Anatolia, and was associated with factors such as misinformation, distrust in healthcare providers, and socioeconomic disparities. Conclusion: Childhood vaccine hesitancy in Türkiye demonstrates marked regional variation but mirrors broader global challenges. Addressing this issue requires strengthening health literacy, enhancing trust in healthcare systems, and counteracting misinformation. The experience of Türkiye provides valuable insights for improving vaccine acceptance strategies worldwide. Keywords: Childhood immunization, health literacy, healthcare mistrust, misinformation and vaccination

29 December 2025 in Turkish Archives of Pediatrics
Verified
Journal Article
Open access
Kubra AykacKubra Aykac
Kubra Aykac
ZDZehra Tan Develi
Zehra Tan Develi
BOBerivan Onel
Berivan Onel
ODOsman Oguz Demir
Osman Oguz Demir
ACAli Bulent Cengiz
Ali Bulent Cengiz
YOYasemin Ozsurekci
Yasemin Ozsurekci
Objective: Human metapneumovirus (hMPV) is a significant agent of respiratory infections in pediatric populations. Despite its global prevalence, the epidemiological characteristics and clinical burden of hMPV infections remain insufficiently recognized. This study aimed to evalu ate the clinical features and outcomes of severe pneumonia among children hospitalized with hMPV infection. Materials and Methods: This retrospective study analyzed pediatric patients diagnosed with hMPV infection at Hacettepe University İhsan Doğramacı Children’s Hospital between January 2018 and December 2024. Demographic, clinical, and laboratory data were systematically reviewed to identify factors associated with severe pneumonia. Results: A total of 116 children with hMPV infection were included, of whom 17.2% (n = 20) devel oped severe pneumonia requiring respiratory support. Notably, 85% (n = 17) of these severe cases occurred in children under 5 years of age, and 90% (n = 18) had underlying chronic medi cal conditions. In cases of non-severe pneumonia, hMPV monoinfection was identified in 74.8% (n = 56) of patients, while 25.2% (n = 19) had coinfections, most commonly involving rhinovirus (14.7%, n = 17). Conversely, among severe pneumonia cases, hMPV monoinfection was predom inant (90%, n = 18), with coinfections detected in only 10% (n = 2). A substantial increase in hospi talization rates was observed in 2024 (36%), potentially indicating an evolving disease severity. Additionally, 1 infection-related mortality (3.1%) was recorded in an older pediatric patient. Conclusion: Severe pneumonia in this single-center series was mainly linked to hMPV monoin fection, with hospitalizations rising in 2024. These findings underscore the clinical impact of hMPV and the need for strengthened surveillance and timely diagnostics, while informing pre ventive strategies, including future vaccines/therapeutics.

10 July 2026 in Mycoses
Verified
Journal Article
Open access
PDF file
Kubra AykacKubra Aykac
Kubra Aykac
ISIlgın Sirin
Ilgın Sirin
TOTurgut Ozdemir
Turgut Ozdemir
ODOsman Oguz Demir
Osman Oguz Demir
AKAylin Irmak Kuruc
Aylin Irmak Kuruc
YOYasemin Ozsurekci
Yasemin Ozsurekci
Background: The Paed‐EQUAL Candida Score was developed to assess adherence to guideline‐recommended management in paediatric candidemia; however, its clinical utility in predicting outcomes remains unclear, particularly in paediatric populations where validation data are scarce. Methods: We conducted a retrospective observational study including paediatric patients diagnosed with candidemia at a tertiary‐care centre between 2014 and 2024. The Paed‐EQUAL Candida Score was calculated for each patient, and its association with 30‐day and 90‐day mortality was evaluated using ROC curve analysis, and optimal cut‐off values were explored. Results: A total of 127 paediatric patients with candidemia were included, of whom 17 (13.4%) died within 30 days and 27 (21.3%) within 90 days. Central venous catheter removal was significantly associated with improved survival at both 30 days (76.4% vs. 35.3%, p = 0.001) and 90 days (77% vs. 48.1%, p = 0.007). Higher adherence to Paed‐EQUAL Candida Score components was observed among survivors, with significantly higher median scores in survivors compared to non‐survivors at 30 days (17 [IQR 14–18] vs. 14 [12–16], p = 0.026). However, the score indicated modest discriminative ability for predicting mortality, with an AUC of 0.667 (95% CI 0.577–0.748) for 30‐day mortality and no significant predictive value for 90‐day mortality (AUC 0.594, 95% CI 0.503–0.680). Conclusion: The Paed‐EQUAL Candida Score demonstrated limited prognostic performance in paediatric candidemia and may have constraints in its ability to support clinical decision‐making, particularly given its modest discriminative capacity. While it remains a potentially useful tool for assessing adherence to quality‐of‐care measures, further refinement or development of paediatric‐specific and outcome‐oriented scoring systems may be needed to improve risk stratification and prediction of clinical outcomes.

30 April 2026 in The Turkish Journal of Pediatrics
Verified
Journal Article
Open access
PDF file
HYHacer Yakın
Hacer Yakın
Kubra AykacKubra Aykac
Kubra Aykac
SISultan İçÖz
Sultan İçÖz
HKHalit Kolukırık
Halit Kolukırık
GGGülce Gerçek
Gülce Gerçek
YOYasemin Ozsurekci
Yasemin Ozsurekci
Background. Influenza remains a major cause of morbidity and mortality in children worldwide, yet vaccination coverage is still suboptimal in many countries. We aimed to understand parental awareness, attitudes, and determinants of vaccine uptake to guide effective strategies for increasing coverage and protecting vulnerable pediatric populations. Method. A cross-sectional study was conducted between October 2023 and May 2024 in 38 hospitals across 23 provinces in Türkiye. Data were collected from 5002 families through face-to-face interviews, with 4404 valid responses analyzed. Results. The overall influenza vaccination rate among children was 4.4% (n=195/4404). Vaccination coverage was slightly higher in high-risk groups compared to non-high-risk groups (5.2% vs. 3.5%, p=0.003). Factors positively associated with vaccination uptake included the presence of chronic illness in the child (15.1% in vaccinated vs. 4.7% in unvaccinated, p